Long-term Prognosis of Patients with Hepatitis B Infection: Causes of Death and Utility of Nucleos(t)ide Analogue Therapy

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2014 Nov 8

PMID 25376770

Citations 5

Authors

Toshifumi Tada

Takashi Kumada

Hidenori Toyoda

Seiki Kiriyama

Makoto Tanikawa

Yasuhiro Hisanaga

Akira Kanamori

Shusuke Kitabtake

Takanori Ito

Affiliations

Soon will be listed here.

Abstract

Background: Long-term nucleos(t)ide analogue (NA) therapy for chronic hepatitis B (CHB) patients has been reported to reduce the risk of hepatocellular carcinoma (HCC) development. However, survival rates and causes of death in CHB patients either treated or not treated with NA therapy are unclear. Therefore, we investigated the prognosis of CHB in both of these groups.

Methods: A total of 919 CHB patients who were treated (n = 189) or not treated (n = 730) with NA therapy were enrolled; of these, 135 were selected from each group by propensity score matching. Survival, mortality from both HCC and non-liver related diseases, and causes of death were analyzed.

Results: In all patients (n = 919), cumulative survival and mortality from both HCC and non-liver related diseases did not differ significantly according to NA therapy status. Of 66 patients who died during the follow-up period, 59.1% died due to liver-related diseases (including HCC); of the remainder, 48.1% died of non-liver related malignancies. In patients selected by propensity score matching (n = 270), cumulative survival and mortality from HCC were significantly improved in those who received NA therapy compared with those who did not (p = 0.015 and 0.018, respectively). Cox proportional hazards models indicated that NA therapy was independently associated with survival of CHB patients (hazard ratio, 0.286; 95% confidence interval, 0.122-0.668; p = 0.004).

Conclusions: Approximately 40% of CHB patients died of non-liver-related diseases. Additionally, in patients who required anti-viral therapy for CHB, NA therapy improved survival and mortality from HCC.

Citing Articles

Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study.

Peng W, Gu H, Cheng D, Chen K, Wu C, Jiang C Front Microbiol. 2023; 14:1185492.

PMID: 37303805 PMC: 10249370. DOI: 10.3389/fmicb.2023.1185492.

Efficacy of Antiviral Treatment in Liver Biopsy-Proven Immune-Tolerant Chronic Hepatitis B Patients: A Retrospective Cohort Study.

Liu N, Yang N, Ma W, Yang S, Hu C, Li J Front Med (Lausanne). 2021; 8:655530.

PMID: 33898489 PMC: 8060436. DOI: 10.3389/fmed.2021.655530.

The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment.

Zhang K, Lin S, Wang M, Huang J, Zhu Y Biomed Res Int. 2020; 2020:5728359.

PMID: 32596332 PMC: 7273491. DOI: 10.1155/2020/5728359.

Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma.

Ding Y, Liu K, Xu Y, Zhao Q, Lou S, Xiang X Cancer Med. 2020; 9(9):3057-3069.

PMID: 32150664 PMC: 7196063. DOI: 10.1002/cam4.2968.

Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.

Ju Y, Jun D, Choi J, Saeed W, Lee H, Oh H World J Gastroenterol. 2018; 24(40):4606-4614.

PMID: 30386110 PMC: 6209577. DOI: 10.3748/wjg.v24.i40.4606.

References

Liaw Y . Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009; 29 Suppl 1:100-7. DOI: 10.1111/j.1478-3231.2008.01941.x. View

Yuen M, Yuan H, Wong D, Yuen J, Wong W, Chan A . Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005; 54(11):1610-4. PMC: 1774768. DOI: 10.1136/gut.2005.065136. View

Liu C, Chen P, Lai M, Kao J, Chen D . Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. J Med Virol. 2004; 74(2):237-45. DOI: 10.1002/jmv.20176. View

Joffe M, Rosenbaum P . Invited commentary: propensity scores. Am J Epidemiol. 1999; 150(4):327-33. DOI: 10.1093/oxfordjournals.aje.a010011. View

Kimura T, Rokuhara A, Matsumoto A, Yagi S, Tanaka E, Kiyosawa K . New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA. J Clin Microbiol. 2003; 41(5):1901-6. PMC: 154683. DOI: 10.1128/JCM.41.5.1901-1906.2003. View

Lai C, Ratziu V, Yuen M, Poynard T . Viral hepatitis B. Lancet. 2003; 362(9401):2089-94. DOI: 10.1016/S0140-6736(03)15108-2. View

Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y . Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol. 2010; 82(4):539-45. DOI: 10.1002/jmv.21686. View

Liaw Y, Kao J, Piratvisuth T, Chan H, Chien R, Liu C . Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2015; 6(3):531-61. DOI: 10.1007/s12072-012-9365-4. View

Chen G, Lin W, Shen F, Iloeje U, London W, Evans A . Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol. 2005; 34(1):132-7. DOI: 10.1093/ije/dyh339. View

10.

Hanley J, McNeil B . The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143(1):29-36. DOI: 10.1148/radiology.143.1.7063747. View

11.

Kato H, Orito E, Sugauchi F, Ueda R, Gish R, Usuda S . Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. J Virol Methods. 2001; 98(2):153-9. DOI: 10.1016/s0166-0934(01)00374-3. View

12.

Lok A, McMahon B . Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3):661-2. DOI: 10.1002/hep.23190. View

13.

Iacobellis A, Fusilli S, Mangia A, Clemente R, Festa V, Giacobbe A . Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. Aliment Pharmacol Ther. 2005; 22(9):769-74. DOI: 10.1111/j.1365-2036.2005.02633.x. View

14.

Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H . Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2012; 58(1):98-107. DOI: 10.1002/hep.26180. View

15.

SZMUNESS W . Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol. 1978; 24:40-69. View

16.

Caturelli E, Castellano L, Fusilli S, Palmentieri B, Niro G, Del Vecchio-Blanco C . Coarse nodular US pattern in hepatic cirrhosis: risk for hepatocellular carcinoma. Radiology. 2003; 226(3):691-7. DOI: 10.1148/radiol.2263011737. View

17.

Rustgi V . Epidemiology of hepatocellular carcinoma. Gastroenterol Clin North Am. 1987; 16(4):545-51. View

18.

Shen L, Li J, Zeng M, Lu L, Fan S, Bao H . Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol. 2006; 12(8):1292-5. PMC: 4124446. DOI: 10.3748/wjg.v12.i8.1292. View

19.

Lai C . Therapeutic advances in chronic hepatitis B. J Gastroenterol Hepatol. 2004; 19 Suppl:S5-9. DOI: 10.1111/j.1440-1746.2003.03391.x. View

20.

Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y . Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2012; 58(3):427-33. DOI: 10.1016/j.jhep.2012.10.025. View